42 completed, 13 active not recruiting, 12 terminated, 6 recruiting. 80 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 80 | Completed 42, Active not recruiting 13, Terminated 12, Recruiting 6, Unknown 6, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Active not recruiting 2, Recruiting 1, Unknown 1 |
Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-11-18 |
| Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders Rituximab infusion, Placebo infusion, Premedications - Anti-MAG Neuropathy | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 90 | 2023-06-29 | 2025-11-24 |
| Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS Rituximab - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 200 | 2023-04-01 | 2023-04-28 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Sint Maartenskliniek | 174 | 2023-02-09 | 2026-02-04 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Completed | Sint Maartenskliniek | 114 | 2023-02-01 | 2026-02-03 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Zanubrutinib, Rituximab, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 799 | 2022-03-10 | 2026-10-15 |
| Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Rituximab, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 40 | 2022-02-28 | 2025-08-01 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-11-04 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 282 | 2021-09-23 | 2026-09-25 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 600 | 2021-09-20 | 2026-01-29 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-11-12 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease Rituximab, Ocrelizumab - Relapsing Remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Haukeland University Hospital | 214 | 2020-11-02 | 2025-06-27 |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | Hoffmann-La Roche | 166 | 2020-05-28 | 2026-03-03 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-11-12 |
Showing 20 of 80. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Non-Hodgkin (12) · Lymphoma, Follicular (9) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, B-Cell (4) · Lymphoma, Mantle-Cell (4) · Multiple Sclerosis, Relapsing-Remitting (4) · Arthritis, Rheumatoid (3) · Lupus Nephritis (3) · Anemia (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Burkitt Lymphoma (2) · Granulomatosis with Polyangiitis (2)
Hoffmann-La Roche (9) · National Cancer Institute (NCI) (9) · The Lymphoma Academic Research Organisation (4) · University Hospital, Tours (4) · German CLL Study Group (3) · Assistance Publique - Hôpitaux de Paris (2) · Genentech, Inc. (2) · Haukeland University Hospital (2) · Imperial College London (2) · Loxo Oncology, Inc. (2) · SecuraBio (2) · Sint Maartenskliniek (2) · University Hospital, Rouen (2) · Amsterdam UMC, location VUmc (1) · Anders Svenningsson (1)
United States (28) · France (26) · Italy (18) · Canada (17) · Australia (16) · Spain (14) · Germany (13) · United Kingdom (13) · Belgium (11) · Sweden (11) · Brazil (10) · Poland (10) · Austria (8) · Hungary (8) · Netherlands (8)
Hagop Youssoufian, MD (2) · Aatke van der Maas (1) · Aatke van der Maas, MD PhD (1) · Anders Svenningsson, MD, PhD (1) · Anders Svenningsson, Professor (1) · Andrew Pettitt, Professor (1) · Barbara Eichhorst, MD (1) · Barbara Eichhorst, MD, Prof. (1) · Benjamin Terrier, MD, PhD (1)
PMID 27695295, PMID 39400109, PMID 39513526, PMID 17687130, PMID 20039413, PMID 20841509, PMID 22231479, PMID 23101480, PMID 24002601, PMID 24265828, PMID 24521993, PMID 24591201, PMID 24720836, PMID 24895339, PMID 25343233, PMID 25686644, PMID 26555944, PMID 26712227, PMID 26867033, PMID 26875824, PMID 28031173, PMID 28251914, PMID 28270229, PMID 28476440, PMID 29061568, PMID 29275118, PMID 30010481, PMID 30089664, PMID 30184451, PMID 30501481, PMID 30719632, PMID 30770362, PMID 30811293, PMID 30837635, PMID 30934066, PMID 31184752, PMID 31365801, PMID 31573078, PMID 31729982, PMID 31806605, PMID 32071431, PMID 32589970, PMID 32601378, PMID 32673385, PMID 32810220, PMID 33097974, PMID 33211799, PMID 33288485, PMID 33439748, PMID 33649098
U10CA021115 (3), U10CA180820 (3), U10CA180821 (3), U10CA180888 (3), 2008 (2), 2014 (2), U10CA180886 (2), U24CA196172 (2), UL1RR024150 (2), 2005 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1)